FDA OKs First Triple Combo Therapy for Cystic Fibrosis FDA OKs First Triple Combo Therapy for Cystic Fibrosis

Trikafta combines elexacaftor, ivacaftor, and tezacaftor for patients 12 years or older with CF and at least one F508del mutation in the CFTR gene.FDA Approvals
Source: Medscape Pharmacist Headlines - Category: Drugs & Pharmacology Tags: Pulmonary Medicine News Alert Source Type: news